A Review of the Existing Grading Schemes and a Proposal for a Modified Grading Scheme for Prostatic Lesions in TRAMP Mice

The transgenic adenocarcinoma of the mouse prostate (TRAMP) model is well established and offers several advantages for the study of chemopreventive agents, including its well-defined course of disease progression and high incidence of poorly differentiated carcinomas within a relatively short length of time. However, there is no consensus on the grading of prostatic lesions in these mice. In particular, agreement is lacking on the criteria for differentiating prostatic intraepithelial neoplasia (PIN) from well-differentiated adenocarcinoma, specifically as it relates to evidence of invasion. This differentiation is critical for evaluating the effects of putative chemopreventive agents on progression to neoplasia. Moreover, only one of the published grading schemes assigns numerical grades to prostatic lesions, which facilitate statistical analysis. Here, we review five currently available grading schemes and propose a refined scheme that provides a useful definition of invasion for the differentiation of PIN from well-differentiated adenocarcinoma and includes a numerical scoring system that accounts for both the most severe and most common histopathological lesions in each of the lobes of the prostate and their distributions. We expect that researchers will find this refined grading scheme to be useful for chemoprevention studies in TRAMP mice.

[1]  S. Kulp,et al.  OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. , 2008, Cancer research.

[2]  R. Cardiff,et al.  Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. , 2008, The American journal of pathology.

[3]  S. Kulp,et al.  Chemopreventive and Bioenergetic Signaling Effects of PDK1/Akt Pathway Inhibition in a Transgenic Mouse Model of Prostate Cancer , 2007, Toxicologic pathology.

[4]  O. Ogawa,et al.  Epithelial stromal tumor of the seminal vesicle , 2006, International journal of urology : official journal of the Japanese Urological Association.

[5]  T. Ratliff Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report From the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee , 2004 .

[6]  M. Rubin,et al.  Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee , 2004, Cancer Research.

[7]  Tsuey-Ming Chen,et al.  Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model , 2003, The Prostate.

[8]  J. Haseman,et al.  A Grading Scheme for the Assessment of Proliferative Lesions of the Mouse Prostate in the TRAMP Model , 2003, Toxicologic pathology.

[9]  B. Foster,et al.  The TRAMP Mouse as a Model for Prostate Cancer , 2001, Current protocols in immunology.

[10]  H. Bonkhoff Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  N. Greenberg,et al.  E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. , 2000, Cancer research.

[12]  B. Foster,et al.  Pathologic progression of autochthonous prostate cancer in the TRAMP model , 1999, Prostate Cancer and Prostatic Diseases.

[13]  M. Kattan,et al.  Androgen-independent prostate cancer progression in the TRAMP model. , 1997, Cancer research.

[14]  J. Rosen,et al.  Metastatic prostate cancer in a transgenic mouse. , 1996, Cancer research.

[15]  N. Greenberg Transgenic models for prostate cancer research. , 1996, Urologic oncology.

[16]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Matusik,et al.  The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. , 1994, Molecular endocrinology.